Table I.
Patient characteristics.
| Characteristic | Result |
|---|---|
| Total patient number | 33 |
| Age, median year (range) | 68 (37–79) |
| Sex, male:Female | 27:6 |
| Nephrectomy, yes:No | 32:1 |
| Histology | |
| Clear cell | 29 |
| Xp11.2 translocation | 2 |
| Papillary | 1 |
| Chromophobe | 1 |
| Sarcomatoid | 1 |
| MSKCC risk classification, Favorable:Intermediate:Poor | |
| At the beginning of systemic therapy | 4:22:7 |
| At the starting of nivolumab | 1:24:8 |
| Metastatic site, 1:2:≥3 | 12:11:10 |
| ECOG PS, 0:1:≥2 | |
| At the beginning of systemic therapy | 24:8:1 |
| At the starting of nivolumab | 14:17:2 |
| Number of prior therapy, 1:2:≥3 | 12:9:12 |
MSKCC, Memorial Sloan-Kettering Cancer Center; ECOG, Eastern Cooperative Oncology Group; PS, performance status.